Ulrike Beckert
About Ulrike Beckert
Ulrike Beckert serves as the Director of Market Access DACH at Deciphera Pharmaceuticals, a position she has held since 2021. She has extensive experience in market access roles across various organizations, including Xcenda and Sobi, and holds a PharmD from Technische Universität Braunschweig.
Current Role at Deciphera Pharmaceuticals
Ulrike Beckert serves as the Director of Market Access DACH at Deciphera Pharmaceuticals. She has held this position since 2021, contributing to the company's market access strategies in the DACH region, which includes Germany, Austria, and Switzerland. Her role involves navigating the complexities of market access to ensure that patients have access to innovative therapies.
Previous Experience at Xcenda
Before joining Deciphera Pharmaceuticals, Ulrike Beckert worked at Xcenda in various roles. She was an Assistant Director, Team Lead Market Access from 2016 to 2017, and prior to that, she served as an Assistant Director, Market Access from 2014 to 2016. Her tenure at Xcenda provided her with extensive experience in market access strategies and team leadership within the pharmaceutical industry.
Experience at Sobi - Swedish Orphan Biovitrum AB
Ulrike Beckert worked at Sobi - Swedish Orphan Biovitrum AB from 2017 to 2021. She held the position of Patient Access Manager DACH for two years before advancing to Senior Patient Access Manager DACH. In these roles, she focused on patient access initiatives, ensuring that patients could access critical therapies in the DACH region.
Educational Background in Pharmacy
Ulrike Beckert studied at Technische Universität Braunschweig, where she earned her PharmD in Pharmacy from 2001 to 2005. This educational foundation provided her with the necessary knowledge and skills to pursue a career in the pharmaceutical industry, particularly in market access and patient access roles.
Research and Teaching Experience
Prior to her industry roles, Ulrike Beckert worked as a Research Scientist and Teaching Fellow at Hannover Medical School from 2009 to 2013. This experience involved conducting research and contributing to academic instruction, further enhancing her expertise in the pharmaceutical field.